Bristol-Myers, ImClone Partnership No Longer Threatened

02/28/2002 | Wall Street Journal, The

Bristol-Myers Squibb reportedly has abandoned its threat to break off its marketing partnership with ImClone. Fears over ImClone's cancer drug Erbitux were quelled, company officials said, after a successful meeting Tuesday between ImClone and the FDA. A source said Bristol-Myers still wants to renegotiate the partnership, but an ImClone spokesman said, "We intend to work under the existing terms."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC